NCT07782879 · Georgia State University
DoubleTake: Effect of Message Exposure Via a Discrete Choice Experiment With Eye-Tracking on Quit Attempts Among Adults Who Smoke Menthol Cigarettes
What this study is about
\<p\>The goal of this clinical trial is to learn how exposure to anti-smoking social media messages affects quitting-related behaviors. Eligible participants will be adults aged 21 or older who have used menthol cigarettes on at least 4 days during the past 30 days.
View original scientific description
\<p\>The goal of this clinical trial is to learn how exposure to anti-smoking social media messages affects quitting-related behaviors. Eligible participants will be adults aged 21 or older who have used menthol cigarettes on at least 4 days during the past 30 days.\</p\> \<br\> \<p\>The main question this study aims to answer is: Does exposure to anti-smoking messages (in the context of a discrete choice experiment \[DCE\] with eye-tracking study) increase quitting-related behaviors over the following 2 weeks?\</p\> \<br\> \<p\>Participants will be randomly assigned to view the messages either immediately or after a 2-week waiting period, allowing researchers to compare quitting-related behaviors between the two groups. The primary outcome is whether participants report making a quit attempt in the 2 weeks following randomization.\</p\> \<br\> \<p\>Participants will:\</p\> \<ul\> \<li\>Complete eligibility screening and baseline questions about demographics and tobacco use.\</li\> \<li\>Be randomly assigned to view the messages immediately or after a 2-week waiting period.\</li\> \<li\>Attend a 1-hour in-person study visit at Georgia State University or the University of California, Santa Barbara.\</li\> \<li\>View 64 anti-smoking social media messages presented in 16 choice sets while their eye movements and pupil dilation are measured using a screen-based eye-tracking device.\</li\> \<li\>Select which messages most attract their attention, which they would be most likely to share, and which would most motivate them to quit smoking.\</li\> \<li\>Complete questions about quitting-related behaviors either during the study visit (waitlist control condition) or through an online questionnaire 2 weeks later (immediate condition).
Interventions
BEHAVIORAL
Message Exposure via Discrete Choice Experiment
Participants will view 64 anti-smoking social media messages, presented across 16 choice sets, in a discrete choice experiment (DCE) with eye-tracking. Within each choice set, participants indicate which message most attracts their attention, which they would be most likely to share or repost, and which would most motivate them to quit smoking.
Primary outcome measures
Quit attempts
Time frame: 2 weeks after message exposure for the immediate intervention arm and 2 weeks before message exposure for the waitlist control arm.
Self-reported quit attempt: Participants will be asked, "Have you made an attempt to quit smoking cigarettes in the past 2 weeks?" Response options will include yes, no, and don't know. Participants who report a quit attempt will be asked, "How long did you stop smoking?" with responses recorded as the number of days, ranging from less than 1 day to 14 days. Participants who report stopping smoking for 1 day or more will be classified as having made a quit attempt for the primary outcome analysis.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age 21+ years
- Smoked menthol cigarettes at least once a week in the past 30 days
- Can speak, read, and write in English
- Willing to participate in an in-person study
Exclusion criteria
- Eye conditions affecting fixation, ocular motility, or central acuity (e.g., strabismus, nystagmus, ptosis, aniridia, maculopathy, advanced cataracts, or other conditions affecting macular fixation or central visual acuity).
- Multifocal or near-infrared-blocking/heavily tinted corrective lenses: bifocal, trifocal, or progressive/varifocal lenses, or coatings that impair eye-tracking. (Single-vision glasses and contact lenses are eligible.)
Where
- Santa Barbara, California
- Atlanta, Georgia
Collaborators
University of California, Santa Barbara, National Cancer Institute (NCI)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Sep 25, 2026 · Source of record for eligibility and locations